The QBI & Gladstone Institute Infectious Disease and Human Health Seminar Series present Pei-Yong Shi, PhD, a John Sealy Distinguished Chair in Innovations in Molecular Biology at University of Texas Medical Branch. Dr. Shi works on RNA virus, drug discovery, and vaccine research. His unique expertise in public health laboratory, pharmaceutical companies, and academia allows him to work on both basic and translational research. He has published more than 300 peer-reviewed papers. His group developed the first reverse genetic systems for the epidemic West Nile virus and Zika virus and discovered flavivirus N7 and 2’O methyltransferase activities. His team also published the first peer-reviewed infectious clone and reporter virus for SARS-CoV-2.

Besides academic excellence, Dr. Shi also has a stellar track record of senior leadership role at industry (e.g., Executive Director at Novartis Institute for Tropical Diseases) where he set up antiviral strategies and executed drug discovery and development. He contributed to the development of Fostemsavir, an FDA-approved HIV drug. Many of his technologies have been licensed to leading pharmaceutical companies for countermeasure development. A recent example is his reporter neutralization assay that has enabled the rapid development of Pfizer’s COVID-19 vaccine, the first vaccine with 95% efficacy in humans.

Title: SARS-CoV-2 Biology and Countermeasure Development

Host: Melanie Ott

Please click the link below to join the webinar:

https://ucsf.zoom.us/j/98751459776?pwd=Q0MxVHlRQzZ5WFltY0M5ZVo5bnljUT09

Passcode: 315228